NCT00694122View on ClinicalTrials.gov

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

PHASE3CompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Type 1 DiabetesDawn Phenomenon

Interventions

DRUG

Lantus (glargine)

Described in Arm Description

Trial Locations (1)

02114

Massachusettes General Hospital/ Diabetes Research Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Sanofi

INDUSTRY

lead

Massachusetts General Hospital

OTHER